The U.S. FDA has given a swift and full approval to Precigen Inc.’s gene therapy, Papzimeos (zopapogene imadenovec), for treating adults with recurrent respiratory papillomatosis (RRP), a rare and ...

The amount of money raised through global biopharma IPOs in the first seven months of 2025 is at the lowest level since 2016, ...